

Australia's Mayne Pharma launches Doryx in US

09 July 2013 | News | By BioSpectrum Bureau



Singapore: Mayne Pharma Group has announced the launch of Doxycycline Hyclate Delayed-Release tablet in the US through their generic products division.

According to IMS Health, Doxycycline Hyclate Delayed-Release Tablets 75 mg and 100 mg had sales of approximately \$24 million for the 12 months ending 30 April 2013.

Mayne Pharma's Doxycycline Hyclate Delayed-Release Tablets, 75mg and 100mg are authorized generic versions of the Doryx 75 mg and 100 mg products.

"We are very excited about the launch of these products which will be the first revenue synergies to materialize from the Metrics, Inc acquisition completed in November 2012. These products will add to Mayne Pharma's growing portfolio of generic products marketed in the US," said Mr Scott Richards, CEO, Mayne Pharma.